DreaMed Diabetes

DreaMed Diabetes is a medical device company providing personalized diabetes treatment optimization solutions. The company was established in 2014 and commercialized its first product, an artificial pancreas technology which was licensed to Medtronic Diabetes and now is part of the Medtronic 780G pump. Since then, DreaMed Diabetes has been vigorously working on the DreaMed Advisor portfolio, decision support tools in diabetes management. DreaMed became the first and only company to receive a CE Mark and FDA clearance for DreaMed Advisor Pro, a decision support system in Type 1 diabetes patients using data from CGM/SMBG and insulin pumps and its current FDA cleared Advisor Platform was expanded to include Type 1 and 2 patients on multiple daily injections. The company is continually developing the DreaMed Advisor portfolio, which will aid all people living with diabetes no matter the insulin therapy or diabetes type, and their healthcare professionals to provide personalized insulin therapy.